PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.32%
Negative revenue growth while AVGO stands at 0.59%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-13.87%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-72.60%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-51.78%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-53.37%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-49.18%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-49.18%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.03%
Share reduction more than 1.5x AVGO's 0.26%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.23%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
0.66%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
329.17%
OCF growth above 1.5x AVGO's 7.23%. David Dodd would confirm a clear edge in underlying cash generation.
25.90%
FCF growth above 1.5x AVGO's 6.62%. David Dodd would verify if the firm’s strategic investments yield superior returns.
53.79%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
17.67%
5Y revenue/share CAGR under 50% of AVGO's 122.61%. Michael Burry would suspect a significant competitive gap or product weakness.
-2.29%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
582.23%
5Y OCF/share CAGR above 1.5x AVGO's 73.80%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-38.49%
Negative 3Y OCF/share CAGR while AVGO stands at 34.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
392.80%
Net income/share CAGR at 50-75% of AVGO's 691.11%. Martin Whitman might question if the firm’s product or cost base lags behind.
140.03%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-41.82%
Negative 3Y CAGR while AVGO is 66.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
80.63%
5Y equity/share CAGR at 50-75% of AVGO's 147.32%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
71.68%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
104.00%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
-78.68%
Negative 5Y dividend/share CAGR while AVGO stands at 71.80%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
15.10%
Below 50% of AVGO's 38.29%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-3.94%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.35%
Inventory shrinking or stable vs. AVGO's 5.71%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
1.30%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
1.11%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
14.36%
Debt growth far above AVGO's 1.06%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-3.29%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
1.26%
SG&A declining or stable vs. AVGO's 14.12%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.